SCHEMBL5747273

SCHEMBL5747273

O=C(Oc1cccc(-c2cccnc2)c1)N1CCN2CCC1CC2

nearest known ligand 0.80

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.60
HTR3A P46098 1/20 0.60
CHRNA3 P32297 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5746072 0.89 CHRNA7 (0.63) CHRNA7HTR3ACHRNA3
SCHEMBL5914752 0.87 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL5914683 0.86 CHRNA7 (0.78) CHRNA7HTR3ACHRNA3
SCHEMBL4700611 0.81 KMO (0.52) CHRNA7
SCHEMBL5914659 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL7554342 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL5914655 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL5914755 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL5914691 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3
SCHEMBL7556010 0.77 CHRNA7 (0.71) CHRNA7HTR3ACHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1231212-B1 Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders PFIZER PROD INC (US) 2006-12-20 EP claimed
US-20060014750-A1 Pharmaceutical compositions for the treatment of CNS and other disorders PFIZER INC 2006-01-19 US claimed
US-20020177591-A1 Pharmaceutical compositions for the treatment of CNS and other discorders PFIZER INC. 2002-11-28 US claimed
EP-1231212-A1 Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders Pfizer Products Inc. (US) 2002-08-14 EP claimed
EP-1231212-B1 Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders PFIZER PROD INC (US) 2006-12-20 EP disclosed
US-20060014750-A1 Pharmaceutical compositions for the treatment of CNS and other disorders PFIZER INC 2006-01-19 US disclosed
US-20020177591-A1 Pharmaceutical compositions for the treatment of CNS and other discorders PFIZER INC. 2002-11-28 US disclosed
EP-1231212-A1 Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders Pfizer Products Inc. (US) 2002-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177591-A1 Pharmaceutical compositions for the treatment of CNS and other discorders CHRNA7, CHRNA5, CHRNA10 CHRNA7 1/4885HTR3A 98/4885CHRNA3 4/4885
US-20060014750-A1 Pharmaceutical compositions for the treatment of CNS and other disorders CHRNA7, CHRNA10, CHRNA5 CHRNA7 1/4885HTR3A 145/4885CHRNA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.